Sponsors (7)
The bill channels substantial, flexible federal capital and expedited authorities to accelerate U.S. commercialization of critical technologies and reduce foreign control risks, but does so by concentrating executive discretion, loosening procedural safeguards, and exposing taxpayers and companies to financial, regulatory, and accountability risks.
U.S.-headquartered tech and biotech startups (scientists, small-business owners, tech workers) gain meaningful new financing (seed-to-mid-stage $1M–$10M investments plus a $300M dedicated biotech pool and ~$975.5M implementation funding) to accelerate R&D and commercialization.
Investors, portfolio companies, Treasury, and the Fund operator get clearer definitions and explicit authorities for what constitutes an "adversarial investment" and for roles and responsibilities, reducing legal uncertainty for deal-making and Fund operations.
Companies working on sensitive technologies have an onshore financing alternative that reduces risk of foreign control of strategic firms, supporting national-security goals.
Taxpayers face substantial financial risk because the bill provides large up‑front funding (~$975.5M plus $300M biotech and $22M/year through FY2040) and contingent authorizations (up to $500M) while the Fund may incur investment losses despite aims to be self-sustaining.
Broad, cross-referenced definitions (e.g., NSTC "critical and emerging technologies," statutory "foreign entity of concern") can unpredictably expand regulatory reach, forcing companies to track evolving lists and raising compliance costs.
The bill concentrates decision-making and discretion in the executive branch (Treasury with Defense/Commerce consultation, Secretary hiring and exemptions) and removes or limits standard APA/PRA procedures, reducing congressional oversight, public notice-and-comment, and judicial review.
Based on analysis of 8 sections of legislative text.
Establishes a Treasury-managed investment fund to make seed-to-mid-stage equity investments in U.S. tech (priority biotech), with governance rules, reporting, and initial funding authorization of ~$975.5M.
Introduced December 3, 2025 by Pete Sessions · Last progress December 3, 2025
Creates a new Independence Investment Fund inside the Department of the Treasury to make seed-to-mid-stage equity investments in U.S.-headquartered technology companies (with biotechnology as a priority), support firms vulnerable to adversarial foreign acquisition, and provide market situational awareness to the federal government. The Treasury Secretary will set strategy in consultation with Defense and Commerce, and an independent managing entity selected through competition will run day-to-day investing. Sets governance and transparency rules, authorizes nearly $1.0 billion for initial funding (with dedicated biotech amounts), allows Treasury to hire up to 25 non‑Title 5 staff, requires annual reporting to Congress, and exempts Secretary actions under the Act from the Paperwork Reduction Act and certain Administrative Procedure Act requirements.